inclusion criteria: * men and women over 18 and under 65. * household contact with a confirmed case of covid-19 by pcr for sars-cov-2. * initiate study medication within 4 days from the last close contact with the index case. * the patient must not present symptoms suggestive of covid19 (cough, dyspnea, fever\> 37.5 c, fatigue, sore throat, myalgia, diarrhoea) at the time of admission to the study and from previous 14 days. * informed consent from the patient or legal representative.

inclusion criteria: * men and women over 18 and under 65. * household contact with a confirmed case of covid-19 by pcr for sars-cov-2. * initiate study medication within 4 days from the last close contact with the index case. * the patient must not present symptoms suggestive of covid19 (cough, dyspnea, fever\> 37.5 c, fatigue, sore throat, myalgia, diarrhoea) at the time of admission to the study and from previous 14 days. * informed consent from the patient or legal representative.

inclusion criteria: - men and women over 18 and under 65. - household contact with a confirmed case of covid-19 by pcr for sars-cov-2. - initiate study medication within 4 days from the last close contact with the index case. - the patient must not present symptoms suggestive of covid19 (cough, dyspnea, fever> 37.5 c, fatigue, sore throat, myalgia, diarrhoea) at the time of admission to the study and from previous 14 days. - informed consent from the patient or legal representative.

inclusion criteria: - men and women over 18 and under 65. - household contact with a confirmed case of covid-19 by pcr for sars-cov-2. - initiate study medication within 4 days from the last close contact with the index case. - the patient must not present symptoms suggestive of covid19 (cough, dyspnea, fever> 37.5 c, fatigue, sore throat, myalgia, diarrhoea) at the time of admission to the study and from previous 14 days. - informed consent from the patient or legal representative.